MEDICLIN AG
MED
ISIN DE0006595101 / Valor 1158721
MEDICLIN AG
UMushroom community rating:
About company
MEDICLIN AG is a healthcare provider based in Germany, specializing in a comprehensive range of medical services. The company operates across the healthcare spectrum, focusing on acute care, rehabilitation (post-acute care), and inpatient nursing care services. With a network of facilities throughout Germany, MEDICLIN is positioned to offer a continuum of care to patients, encompassing immediate medical treatment, recovery, and long-term care. This integrated approach ensures that patients receive tailored healthcare services designed to meet their individual needs, from initial diagnosis through to rehabilitation and beyond. MEDICLIN's commitment to offering professional medical services is central to its operations, aiming to provide high-quality care across its various healthcare domains.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (26.07.2026):
MEDICLIN AG — Q4 2025: In Q4 2025 MEDICLIN reported quarterly revenue of EUR 197.6m and EBITDA of EUR 27.6m (EBITDA margin 14.0%). For full-year 2025 the Group posted revenue of EUR 784.5m (+4.8% y/y), EBITDA EUR 115.6m (+11.4% y/y) and EBIT EUR 55.4m (+3.5% y/y). Earnings per share were EUR 0.01 in Q4 and EUR 0.54 for FY 2025. Operating cash flow was EUR 26.8m in Q4 and EUR 102.4m for the year (+27.1%). Net financial debt at end‑Q4 2025 was a net cash position of around EUR -30.4m. The Management Board proposes a dividend of EUR 0.04 per share and issues guidance for 2026 of revenue growth of 3.5–6.5% and EBIT of EUR 57–72m.
Quarterly revenue and margin
Q4 2025 revenue: EUR 197.6m. Q4 EBITDA EUR 27.6m (margin 14.0%); Q4 EBIT EUR 6.5m (margin 3.3%). Quarterly performance followed the seasonal and operational pattern shown across 2025 (Q1–Q4: 184.8 / 199.0 / 203.1 / 197.6 EURm).
Full-year profitability
FY 2025 revenue EUR 784.49m (+4.8% vs. 2024). FY EBITDA EUR 115.58m (+11.4%), EBITDA margin 14.7% (up 0.8 pp). FY EBIT EUR 55.36m (+3.5%), EBIT margin steady at 7.1%.
Earnings per share & dividend
Earnings per share: Q4 2025 EUR 0.01; FY 2025 EUR 0.54 (+3.8% y/y). The Management Board will propose a dividend of EUR 0.04 per share at the Annual General Meeting (same as prior year).
Cash flow and balance sheet
Operating cash flow Q4 EUR 26.8m; FY operating cash flow EUR 102.44m (+27.1% y/y; EUR 2.16 per share). Cash and equivalents at year-end ~EUR 72.2m (down vs. 2024). Net financial debt at end‑Q4 reported approx. EUR -30.4m (net cash); financial liabilities to banks reduced substantially vs. prior year (EUR 14.9m vs. EUR 67.0m).
Operational metrics
Occupancy rate improved to 86.6% (up 1.1 pp). Inpatient cases 108,524 (+1.0% y/y). Number of beds at 31.12.2025: 8,189 (+0.4%). Average full‑time employees for the year: 7,006 (+1.7%).
Capital expenditure & subsidies
Gross additions (ex‑IFRS16) for FY 2025: EUR 55.4m (+20.0% y/y). Of this, subsidies increased materially to EUR 30.6m (previous year EUR 9.3m), supporting investments in facilities and projects. Q4 capex was EUR 18.8m.
Outlook for 2026
Management guidance for 2026: Group revenue growth of 3.5–6.5% and Group EBIT of EUR 57–72m (EBIT margin targeted ~7.0–8.0%). Guidance is conditional on no substantial deterioration in the German economy due to geopolitical risks.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
231 M
Market cap (USD)
3,647
Daily traded volume (Shares)
2.42 / 2.34
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
